Chlamydia trachomatis genital tract infections remain a significant national and global health problem that is especially important in women's reproductive health. Recognition of the role C. trachomatis plays in the development of severe upper genital tract disease coupled with recent observations demonstrating an increase in the incidence of chlamydial genital tract infections associated with the most effective screen and treatment programs highlight the need to learn more about the epidemiology and pathogenesis of chlamydial genital tract disease to ensure the most effective control measures are developed and implemented. We propose to study a murine model of chlamydial genital tract infection to determine if arrested immunity helps explain the increased incidence of chlamydial genital tract infections. In our first aim we will evaluate if early antibiotic intervention impacts development of an immune response to primary infection, susceptibility to reinfection and most importantly development of upper genital tract sequelae and its severity.
This aim will be complemented by a second aim, which will examine host genetics in the development of upper genital tract disease. Preliminary data are presented to validate the use of recombinant inbred (BXD) mice as a powerful method to study host factors and disease severity. We have established intervals on mouse chromosomes 3 and 19 that correlate with oviduct and uterine involvement and disease severity. Interestingly, these loci have syntenous intervals on human chromosomes 1 and 11, making it highly likely that the approaches we have chosen to study in mice will have translational relevance to human disease. Results of this study will be important in improving our understanding of arrested immunity and chlamydial genital tract disease, the impact of arrested immunity on upper tract disease severity and the role of host genetic factors in the development of chlamydial upper genital tract disease.

Public Health Relevance

Chlamydia trachomatis is the most frequently reported sexually transmitted infection in the United States and an important public health problem because it causes upper genital tract complications in women. The incidence of chlamydial genital tract infections is increasing in the United Sates at an alarming rate despite implementation of excellent screening and treatment programs during the past 15 years, making it imperative to learn more about why this important human pathogen is so difficult to control. Work proposed in this application is designed to provide new information on why chlamydial genital tract infections are on the rise, why some individuals are more likely to have severe complications of infections than others, and how we can best protect ourselves from this disease by understanding the genetic basis of serious chlamydial disease development and how it may be prevented.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI019782-28
Application #
8645572
Study Section
Special Emphasis Panel (ZRG1-IDM-N (02))
Program Officer
Hiltke, Thomas J
Project Start
1982-08-01
Project End
2015-04-30
Budget Start
2014-05-01
Budget End
2015-04-30
Support Year
28
Fiscal Year
2014
Total Cost
$375,000
Indirect Cost
$125,000
Name
University of Tennessee Health Science Center
Department
Other Basic Sciences
Type
Schools of Medicine
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Grayston, J Thomas; Belland, Robert J; Byrne, Gerald I et al. (2015) Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested. Pathog Dis 73:1-9
Peters, Jan; Byrne, Gerald I (2015) Chlamydia trachomatis growth depends on eukaryotic cholesterol esterification and is affected by Acyl-CoA:cholesterol acyltransferase inhibition. Pathog Dis 73:ftv028
Patil, Renukadevi; Szabó, Erzsébet; Fells, James I et al. (2015) Combined mitigation of the gastrointestinal and hematopoietic acute radiation syndromes by an LPA2 receptor-specific nonlipid agonist. Chem Biol 22:206-16
Bonner, Carol A; Byrne, Gerald I; Jensen, Roy A (2014) Chlamydia exploit the mammalian tryptophan-depletion defense strategy as a counter-defensive cue to trigger a survival state of persistence. Front Cell Infect Microbiol 4:17
Bavoil, Patrik M; Byrne, Gerald I (2014) Analysis of CPAF mutants: new functions, new questions (the ins and outs of a chlamydial protease). Pathog Dis 71:287-91
Jonsson, Colleen B; Cole, Kelly Stefano; Roy, Chad J et al. (2013) Challenges and Practices in Building and Implementing Biosafety and Biosecurity Programs to Enable Basic and Translational Research with Select Agents. J Bioterror Biodef Suppl 3:12634
Abdelsamed, Hossam; Peters, Jan; Byrne, Gerald I (2013) Genetic variation in Chlamydia trachomatis and their hosts: impact on disease severity and tissue tropism. Future Microbiol 8:1129-1146
Miyairi, Isao; Ziebarth, Jesse; Laxton, Jonathan D et al. (2012) Host genetics and Chlamydia disease: prediction and validation of disease severity mechanisms. PLoS One 7:e33781
Ziebarth, Jesse D; Bhattacharya, Anindya; Chen, Anlong et al. (2012) PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res 40:D216-21
Peters, Jan; Onguri, Vijaya; Nishimoto, Satoru K et al. (2012) The Chlamydia trachomatis CT149 protein exhibits esterase activity in vitro and catalyzes cholesteryl ester hydrolysis when expressed in HeLa cells. Microbes Infect 14:1196-204

Showing the most recent 10 out of 43 publications